Clinical Trials Logo

Diabetes Mellitus, Type 2 clinical trials

View clinical trials related to Diabetes Mellitus, Type 2.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT06083675 Withdrawn - Clinical trials for Diabetes Mellitus, Type 2

Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes

Start date: January 26, 2024
Phase: Phase 3
Study type: Interventional

This study compares the medicines semaglutide with empagliflozin or metformin in people with newly diagnosed type 2 diabetes. This study will look mainly at how well participant's blood sugar and body weight are controlled when they are taking the study medicines. Participants will either get semaglutide tablets, empagliflozin tablets or metformin tablets. Which treatment participants will get is decided by chance. Currently, doses of 3 milligram (mg), 7 mg and 14 mg semaglutide tablets (Rybelsus) can be prescribed in some countries. 25 mg and 50 mg semaglutide tablets are new doses. 10 mg and 25 mg empagliflozin tablets (Jardiance) can be prescribed in some countries. 500 mg metformin tablets (STADA) can be prescribed in some countries. Participants will get 1 to 4 tablets per day for 104 weeks. The study will last for about 2 years and 7 weeks (111 weeks). Participants should not have been treated for weight management 90 days before screening or never been treated with any medicine for type 2 diabetes (except diabetes during pregnancy) before screening. Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period.

NCT ID: NCT05908513 Withdrawn - Diabetes Mellitus Clinical Trials

NAC Treatment and Outcomes in Patients With Advanced Atherosclerosis and DM

RENEWAL
Start date: October 15, 2021
Phase: Phase 1
Study type: Interventional

Atherosclerosis and diabetes are related to coronary artery disease and peripheral artery disease. The mechanisms are related to increased reactive oxygen species (ROS) formation and inflammatory cytokine secretion. However, simply using antioxidant or anti-inflammatory therapies has no optimal outcomes. On the other hand, N-acetylcysteine (NAC) which has both antioxidant and anti-inflammatory effects could effectively attenuate ROS production and reduce vascular inflammation. Hence, we will investigate the effect of NAC treatment on the outcomes in patients with advanced atherosclerotic heart diseases and patients with diabetes combined with significant peripheral artery disease.

NCT ID: NCT05791929 Withdrawn - Clinical trials for Diabetes Mellitus, Type 2

LSCI and Thermography in Diabetic Foot Patients Affected by Ulcer(s): (MY-FOOT-B)

MY-FOOT-B
Start date: April 13, 2023
Phase:
Study type: Observational

The objective of this observational study is to predict healing at 26 weeks after the first visit in patients affected by the first ulcer, by means of combined data monitoring of Laser Speckle Contrast Imaging (LSCI) and temperature measurements during patient visits in hospital. In order to achieve this objective, study aims to produce a logistic regression model and then evaluate its prognostic ability by means of the area under the curve (AUC) of the receiver-operating-characteristics (ROC) curve. Patients with diabetes mellitus and suffering from ulcer and receiving health care will undergo regular microcirculatory measurements including LSCI scans in and around the ulcer location and thermography.

NCT ID: NCT05726409 Withdrawn - Clinical trials for Diabetes Mellitus, Type 2

Mobile Application to Create Healthy Food Preparation Habits for Patients With Diabetes and Prediabetes

Start date: September 2023
Phase: N/A
Study type: Interventional

Boston Medical Center (BMC) serves many underserved, low-income patients and has developed an innovative strategy to combat food insecurity including a preventative food pantry, a teaching kitchen, and a rooftop farm that provides fresh produce directly to the patients. The presence of this well-established, three-pronged approach places BMC in an ideal position to develop a nutritional education intervention that supports experiential learning in this high-risk population. For this first exploratory study, 75 enrolled participants will be given a free mobile application with recipes designed to build habits. Participants will cook at least three meals weekly for two months using the app. Self-reported survey data and activity on the app will be collected and used to assess the feasibility of teaching cooking skills through a mobile application.

NCT ID: NCT05696964 Withdrawn - Clinical trials for Diabetes Mellitus, Type 2

Improving Relationships Using Motivational Interviewing

IRMIT
Start date: February 1, 2024
Phase: N/A
Study type: Interventional

This research aims to optimize patient-clinician relationships through motivational interviewing training in a Federally Qualified Health Center (FQHC) to improve health outcomes for African American patients with Type 2 diabetes.

NCT ID: NCT05669560 Withdrawn - Diabetes Mellitus Clinical Trials

Efficacy of Hydrogen Peroxide Gel on Periodontitis With Diabetes

Peroxide gel
Start date: January 20, 2023
Phase: Early Phase 1
Study type: Interventional

Periodontitis is a chronic infectious disease characterized by loss of tooth supporting periodontal structures and alveolar bone. In the U.S. and worldwide, periodontitis is the major cause of tooth loss in adults. Type 2 Diabetes mellitus (T2DM) is a complex disease that affects 13-15 million Americans and is associated with a variety of serious complications. T2DM is well established as a strong systemic risk factor for periodontitis. The severity and prevalence of periodontitis is much higher in patients with diabetes. This relationship may be bi-directional.

NCT ID: NCT05663554 Withdrawn - Obesity Clinical Trials

Improving Glycemic Control Using a Virtual Weight Control Program Among Adults With Type 2 Diabetes

VITAL-2
Start date: January 15, 2023
Phase: N/A
Study type: Interventional

The study is a randomized clinical trial with the primary aim of determining the effectiveness of the WW intervention at reducing HbA1c in patients with type 2 diabetes.

NCT ID: NCT05541120 Withdrawn - Clinical trials for Diabetes Mellitus, Type 2

Effect of Remote Patient Monitoring and Patient Education on Patient Activation and Glycemic Control in Individuals With Type 2 Diabetes

Start date: October 18, 2022
Phase: N/A
Study type: Interventional

This is a randomized controlled trial of the use of Remote Patient Monitoring (RPM) compared to usual care among rural patients with poorly controlled type 2 diabetes. Usual care is defined as participation in Living Well with Diabetes/Virtual Diabetes Self-Management Program and Primary Care Provider evaluation and management at the providers' discretion, including medication adjustment or interventions, and other types of interventions depending on clinical judgement.

NCT ID: NCT05479591 Withdrawn - Clinical trials for Diabetes Mellitus, Type 2

A Research Study Looking at Blood Sugar Control in People With Type 2 Diabetes Previously Treated With Premix Insulin and Initiating Treatment With Insulin Degludec/Liraglutide (IDegLira) in Local Clinical Practice in Croatia

GLIDE
Start date: July 30, 2022
Phase:
Study type: Observational

The purpose of this study is to look at the blood sugar control in participants with type 2 diabetes previously treated with premix insulins and initiating treatment with IDegLira. Participants will get IDegLira as prescribed by study doctor regardless of participant's decision to participate in the study. Decision to initiate treatment with IDegLira will be made by study doctor independent from the study. The study will last for about 36 weeks. Participants will be asked questions about their health and diabetes treatment and lab tests as part of their normal doctor's appointment.

NCT ID: NCT05473286 Withdrawn - Clinical trials for Diabetes Mellitus, Type 2

A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice

PIONEER REAL
Start date: September 30, 2022
Phase:
Study type: Observational

The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower their blood sugar levels. Participants will get Rybelsus® as prescribed to them by the study doctor. The study will last for about 34-44 weeks. Participants will be asked to complete questionnaires about how they take their Rybelsus® tablets. Participants will complete the questionnaires during their normally scheduled visit with the study doctor.